Regulatory & Compliance

Is Imbruvica Revolutionizing MCL Survival Rates in the EU?
Research & Development Is Imbruvica Revolutionizing MCL Survival Rates in the EU?

The cancer treatment market is witnessing monumental shifts as leading innovations pave a new path, notably in the fight against mantle cell lymphoma (MCL). With Imbruvica (ibrutinib) being sanctioned by the European Commission as a frontline treatment, a significant transformation in cancer

Can Elahere Transform Ovarian Cancer Treatment in the UK?
Management & Regulatory Can Elahere Transform Ovarian Cancer Treatment in the UK?

Imagine a world where ovarian cancer treatment defies conventional boundaries, offering renewed optimism to thousands of patients facing limited options. This vision takes form with Elahere, an emerging therapeutic choice now approved in the UK for those resistant to platinum-based

Will Blenrep Transform Multiple Myeloma Treatment in Europe?
Management & Regulatory Will Blenrep Transform Multiple Myeloma Treatment in Europe?

With multiple myeloma cases surpassing 50,000 annually across Europe, the quest for a more effective treatment has never been more urgent. Despite its classification as a rare cancer, its profound impact on affected individuals and healthcare systems is undeniable. Imagine a treatment that could

Can Darzalex Delay Multiple Myeloma's Onset?
Management & Regulatory Can Darzalex Delay Multiple Myeloma's Onset?

In the realm of biopharmaceutical innovation, Ivan Kairatov stands as a distinguished figure, renowned for his expertise in research and development within the industry. Today, we delve into the groundbreaking approval by the European Commission of Darzalex for treating high-risk smouldering

Is Brukinsa the Key to Tackling Relapsed Mantle Cell Lymphoma?
Management & Regulatory Is Brukinsa the Key to Tackling Relapsed Mantle Cell Lymphoma?

In today's discussion, we have the pleasure of speaking with Ivan Kairatov, a seasoned Biopharma expert known for his profound insights into the tech and innovation driving the pharmaceutical industry. With extensive experience in research and development, Ivan is here to share his knowledge about

AI and Costs Shape Future of Decentralized Clinical Trials
Research & Development AI and Costs Shape Future of Decentralized Clinical Trials

In the realm of pharmaceutical research, decentralized clinical trials (DCTs) are emerging as a transformative force, promising to redefine how clinical studies are conducted. These trials address the traditional challenges that have long plagued clinical research, including limited participant

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later